Pharmacology of sedative-analgesic agents: Dexmedetomidine, remifentanil, ketamine, volatile anesthetics, and the role of peripheral mu antagonists

Anesthesiology Clinics

Volumn 29, Issue 4, 2011, Pages 587-605

  Panzer, Oliver ^a   Moitra, Vivek ^a   Sladen, Robert N ^a  

^a Columbia University ^*  (United States)

Author keywords

Analgesia; Dexmedetomidine; Ketamine; Remifentanil; Sedation; Volatile anesthetics

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; ANALGESIC AGENT; DESFLURANE; DEXMEDETOMIDINE; INHALATION ANESTHETIC AGENT; ISOFLURANE; KETAMINE; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; REMIFENTANIL; SEDATIVE AGENT; SEVOFLURANE;

ANALGESIA; BRADYCARDIA; CONSTIPATION; DELIRIUM; DRUG EFFECT; DRUG MECHANISM; HALLUCINATION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOTENSION; ILEUS; INHALATION ANESTHESIA; INTESTINE MOTILITY; LACRIMATION; MUSCLE RIGIDITY; MYDRIASIS; MYOCLONUS; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SALIVATION; SEDATION; SIDE EFFECT; STOMACH EMPTYING; SWEATING; TACHYCARDIA; URINE RETENTION; VOMITING; WITHDRAWAL SYNDROME;

EID: 81055138806     PISSN: 19322275     EISSN: 22103538     Source Type: Journal    
DOI: 10.1016/j.anclin.2011.09.002     Document Type: Review

References (161)

1. Scheinin H., Aantaa R., Anttila M., et al. Reversal of the sedative and sympatholytic effects of dexmedetomidine with a specific alpha2-adrenoceptor antagonist atipamezole: a pharmacodynamic and kinetic study in healthy volunteers. Anesthesiology 1998, 89:574-584.
2. Ma D., Hossain M., Rajakumaraswamy N., et al. Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol 2004, 502:87-97.
3. Fagerholm V., Scheinin M., Haaparanta M. Alpha2A-adrenoceptor antagonism increases insulin secretion and synergistically augments the insulinotropic effect of glibenclamide in mice. Br J Pharmacol 2008, 154:1287-1296.
4. Takada K., Clark D.J., Davies M.F., et al. Meperidine exerts agonist activity at the alpha(2B)-adrenoceptor subtype. Anesthesiology 2002, 96:1420-1426.
5. Fagerholm V., Rokka J., Nyman L., et al. Autoradiographic characterization of alpha(2C)-adrenoceptors in the human striatum. Synapse 2008, 62:508-515.
6. Moura E., Afonso J., Hein L., et al. Alpha2-adrenoceptor subtypes involved in the regulation of catecholamine release from the adrenal medulla of mice. Br J Pharmacol 2006, 149:1049-1058.
7. Khan Z.P., Ferguson C.N., Jones R.M. Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia 1999, 54:146-165.
8. Takamatsu I., Iwase A., Ozaki M., et al. Dexmedetomidine reduces long-term potentiation in mouse hippocampus. Anesthesiology 2008, 108:94-102.
9. Venn R.M., Karol M.D., Grounds R.M. Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive caret. Br J Anaesth 2002, 88:669-675.
10. Vilo S., Rautiainen P., Kaisti K., et al. Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age. Br J Anaesth 2008, 100:697-700.
11. Petroz G.C., Sikich N., James M., et al. A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. Anesthesiology 2006, 105:1098-1110.
12. Kivisto K.T., Kallio A., Neuvonen P.J. Pharmacokinetics and pharmacodynamics of transdermal dexmedetomidine. Eur J Clin Pharmacol 1994, 46:345-349.
13. Anttila M., Penttila J., Helminen A., et al. Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. Br J Clin Pharmacol 2003, 56:691-693.
14. De Wolf A.M., Fragen R.J., Avram M.J., et al. The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. Anesth Analg 2001, 93:1205-1209.
15. Dutta S., Lal R., Karol M.D., et al. Influence of cardiac output on dexmedetomidine pharmacokinetics. J Pharm Sci 2000, 89:519-527.
16. Talke P., Richardson C.A., Scheinin M., et al. Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. Anesth Analg 1997, 85:1136-1142.
17. Kallio A., Scheinin M., Koulu M., et al. Effects of dexmedetomidine, a selective alpha 2-adrenoceptor agonist, on hemodynamic control mechanisms. Clin Pharmacol Ther 1989, 46:33-42.
18. Bulow N.M., Barbosa N.V., Rocha J.B. Opioid consumption in total intravenous anesthesia is reduced with dexmedetomidine: a comparative study with remifentanil in gynecologic videolaparoscopic surgery. J Clin Anesth 2007, 19:280-285.
19. Ebert T.J., Hall J.E., Barney J.A., et al. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology 2000, 93:382-394.
20. Jorden V.S., Pousman R.M., Sanford M.M., et al. Dexmedetomidine overdose in the perioperative setting. Ann Pharmacother 2004, 38:803-807.
21. Ramsay M.A., Luterman D.L. Dexmedetomidine as a total intravenous anesthetic agent. Anesthesiology 2004, 101:787-790.
22. Jalowiecki P., Rudner R., Gonciarz M., et al. Sole use of dexmedetomidine has limited utility for conscious sedation during outpatient colonoscopy. Anesthesiology 2005, 103:269-273.
23. Muntazar M., Kumar F.C. Cardiac arrest, a preventable yet a possible risk of dexmedetomidine: fact or fiction?. Anesthesiology 2004, 101:1478-1479. [author reply: 9-80].
24. Shah A.N., Koneru J., Nicoara A., et al. Dexmedetomidine related cardiac arrest in a patient with permanent pacemaker; a cautionary tale. Pacing Clin Electrophysiol 2007, 30:1158-1160.
25. Riker R.R., Shehabi Y., Bokesch P.M., et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009, 301:489-499.
26. Venn M., Newman J., Grounds M. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med 2003, 29:201-207.
27. Reid K., Hayashi Y., Guo T.Z., et al. Chronic administration of an alpha 2 adrenergic agonist desensitizes rats to the anesthetic effects of dexmedetomidine. Pharmacol Biochem Behav 1994, 47:171-175.
28. Turkmen A., Altan A., Turgut N., et al. The correlation between the Richmond agitation-sedation scale and bispectral index during dexmedetomidine sedation. Eur J Anaesthesiol 2006, 23:300-304.
29. Aantaa R. Assessment of the sedative effects of dexmedetomidine, an alpha 2-adrenoceptor agonist, with analysis of saccadic eye movements. Pharmacol Toxicol 1991, 68:394-398.
30. Bekker A., Sturaitis M.K. Dexmedetomidine for neurological surgery. Neurosurgery 2005, 57(1 Suppl):1-10. [discussion: 1-10].
31. Elias W.J., Durieux M.E., Huss D., et al. Dexmedetomidine and arousal affect subthalamic neurons. Mov Disord 2008, 23:1317-1320.
32. Girard T.D., Kress J.P., Fuchs B.D., et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet 2008, 371:126-134.
33. Kress J.P., O'Connor M.F., Pohlman A.S., et al. Sedation of critically ill patients during mechanical ventilation. A comparison of propofol and midazolam. Am J Respir Crit Care Med 1996, 153:1012-1018.
34. Hsu Y.W., Cortinez L.I., Robertson K.M., et al. Dexmedetomidine pharmacodynamics: part I: crossover comparison of the respiratory effects of dexmedetomidine and remifentanil in healthy volunteers. Anesthesiology 2004, 101:1066-1076.
35. Nelson L.E., Lu J., Guo T., et al. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology 2003, 98:428-436.
36. Coull J.T., Jones M.E., Egan T.D., et al. Attentional effects of noradrenaline vary with arousal level: selective activation of thalamic pulvinar in humans. Neuroimage 2004, 22:315-322.
37. Kauppila T., Kemppainen P., Tanila H., et al. Effect of systemic medetomidine, an alpha 2 adrenoceptor agonist, on experimental pain in humans. Anesthesiology 1991, 74:3-8.
38. Arain S.R., Ebert T.J. The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg 2002, 95:461-466.
39. Arain S.R., Ruehlow R.M., Uhrich T.D., et al. The efficacy of dexmedetomidine versus morphine for postoperative analgesia after major inpatient surgery. Anesth Analg 2004, 98:153-158.
40. Al-Metwalli R.R., Mowafi H.A., Ismail S.A., et al. Effect of intra-articular dexmedetomidine on postoperative analgesia after arthroscopic knee surgery. Br J Anaesth 2008, 101:395-399.
41. Yoshitomi T., Kohjitani A., Maeda S., et al. Dexmedetomidine enhances the local anesthetic action of lidocaine via an alpha-2A adrenoceptor. Anesth Analg 2008, 107:96-101.
42. Deutsch E., Tobias J.D. Hemodynamic and respiratory changes following dexmedetomidine administration during general anesthesia: sevoflurane vs desflurane. Paediatr Anaesth 2007, 17:438-444.
43. Koroglu A., Teksan H., Sagir O., et al. A comparison of the sedative, hemodynamic, and respiratory effects of dexmedetomidine and propofol in children undergoing magnetic resonance imaging. Anesth Analg 2006, 103:63-67.
44. Venn R.M., Hell J., Grounds R.M. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care 2000, 4:302-308.
45. Arpino P.A., Kalafatas K., Thompson B.T. Feasibility of dexmedetomidine in facilitating extubation in the intensive care unit. J Clin Pharm Ther 2008, 33:25-30.
46. Siobal M.S., Kallet R.H., Kivett V.A., et al. Use of dexmedetomidine to facilitate extubation in surgical intensive-care-unit patients who failed previous weaning attempts following prolonged mechanical ventilation: a pilot study. Respir Care 2006, 51:492-496.
47. Akada S., Takeda S., Yoshida Y., et al. The efficacy of dexmedetomidine in patients with noninvasive ventilation: a preliminary study. Anesth Analg 2008, 107:167-170.
48. Bergese S.D., Khabiri B., Roberts W.D., et al. Dexmedetomidine for conscious sedation in difficult awake fiberoptic intubation cases. J Clin Anesth 2007, 19:141-144.
49. Grant S.A., Breslin D.S., MacLeod D.B., et al. Dexmedetomidine infusion for sedation during fiberoptic intubation: a report of three cases. J Clin Anesth 2004, 16:124-126.
50. Stamenkovic D.M., Hassid M. Dexmedetomidine for fiberoptic intubation of a patient with severe mental retardation and atlantoaxial instability. Acta Anaesthesiol Scand 2006, 50:1314-1315.
51. Doufas A.G., Lin C.M., Suleman M.I., et al. Dexmedetomidine and meperidine additively reduce the shivering threshold in humans. Stroke 2003, 34:1218-1223.
52. Elvan E.G., Oc B., Uzun S., et al. Dexmedetomidine and postoperative shivering in patients undergoing elective abdominal hysterectomy. European journal of anaesthesiology 2008, 25:357-364.
53. Tobias J.D. Bradycardia during dexmedetomidine and therapeutic hypothermia. J Intensive Care Med 2008, 23:403-408.
54. Herr D.L., Sum-Ping S.T., England M. ICU sedation after coronary artery bypass graft surgery: dexmedetomidine-based versus propofol-based sedation regimens. J Cardiothorac Vasc Anesth 2003, 17:576-584.
55. Oliver M.F., Goldman L., Julian D.G., et al. Effect of mivazerol on perioperative cardiac complications during non-cardiac surgery in patients with coronary heart disease: the European Mivazerol Trial (EMIT). Anesthesiology 1999, 91:951-961.
56. Wijeysundera D.N., Naik J.S., Beattie W.S. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. Am J Med 2003, 114:742-752.
57. Biccard B.M., Goga S., de Beurs J. Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials. Anaesthesia 2008, 63:4-14.
58. Dahmani S., Rouelle D., Gressens P., et al. Effects of dexmedetomidine on hippocampal focal adhesion kinase tyrosine phosphorylation in physiologic and ischemic conditions. Anesthesiology 2005, 103:969-977.
59. Prielipp R.C., Wall M.H., Tobin J.R., et al. Dexmedetomidine-induced sedation in volunteers decreases regional and global cerebral blood flow. Anesth Analg 2002, 95:1052-1059. table of contents.
60. Zornow M.H., Maze M., Dyck J.B., et al. Dexmedetomidine decreases cerebral blood flow velocity in humans. J Cereb Blood Flow Metab 1993, 13:350-353.
61. Drummond J.C., Dao A.V., Roth D.M., et al. Effect of dexmedetomidine on cerebral blood flow velocity, cerebral metabolic rate, and carbon dioxide response in normal humans. Anesthesiology 2008, 108:225-232.
62. Maccioli G.A. Dexmedetomidine to facilitate drug withdrawal. Anesthesiology 2003, 98:575-577.
63. Multz A.S. Prolonged dexmedetomidine infusion as an adjunct in treating sedation-induced withdrawal. Anesth Analg 2003, 96:1054-1055. table of contents.
64. Baddigam K., Russo P., Russo J., et al. Dexmedetomidine in the treatment of withdrawal syndromes in cardiothoracic surgery patients. J Intensive Care Med 2005, 20:118-123.
65. Kent C.D., Kaufman B.S., Lowy J. Dexmedetomidine facilitates the withdrawal of ventilatory support in palliative care. Anesthesiology 2005, 103:439-441.
66. Farag E., Chahlavi A., Argalious M., et al. Using dexmedetomidine to manage patients with cocaine and opioid withdrawal, who are undergoing cerebral angioplasty for cerebral vasospasm. Anesth Analg 2006, 103:1618-1620.
67. Rovasalo A., Tohmo H., Aantaa R., et al. Dexmedetomidine as an adjuvant in the treatment of alcohol withdrawal delirium: a case report. Gen Hosp Psychiatry 2006, 28:362-363.
68. Stemp L.I., Karras G.E. Dexmedetomidine facilitates withdrawal of ventilatory support. Anesthesiology 2006, 104:890. [author reply: 890].
69. Darrouj J., Puri N., Prince E., et al. Dexmedetomidine infusion as adjunctive therapy to benzodiazepines for acute alcohol withdrawal. Ann Pharmacother 2008, 42:1703-1705.
70. Junaid A., Cui L., Penner S.B., et al. Regulation of aquaporin-2 expression by the alpha(2)-adrenoceptor agonist clonidine in the rat. J Pharmacol Exp Ther 1999, 291:920-923.
71. Rouch A.J., Kudo L.H., Hebert C. Dexmedetomidine inhibits osmotic water permeability in the rat cortical collecting duct. J Pharmacol Exp Ther 1997, 281:62-69.
72. Intengan H.D., Smyth D.D. Clonidine-induced increase in osmolar clearance and free water clearance via activation of two distinct alpha 2-adrenoceptor sites. Br J Pharmacol 1996, 119:663-670.
73. Billings F.T., Chen S.W., Kim M., et al. Alpha2-Adrenergic agonists protect against radiocontrast-induced nephropathy in mice. Am J Physiol Renal Physiol 2008, 295:F741-F748.
74. Taoda M., Adachi Y.U., Uchihashi Y., et al. Effect of dexmedetomidine on the release of [3H]-noradrenaline from rat kidney cortex slices: characterization of alpha2-adrenoceptor. Neurochem Int 2001, 38:317-322.
75. Kocoglu H., Ozturk H., Yilmaz F., et al. Effect of dexmedetomidine on ischemia-reperfusion injury in rat kidney: a histopathologic study. Ren Fail 2009, 31:70-74.
76. Wilhelm W., Kreuer S. The place for short-acting opioids: special emphasis on remifentanil. Crit Care 2008, 12(Suppl 3):S5. [abstract].
77. Martin J., Franck M., Sigel S., et al. Changes in sedation management in German intensive care units between 2002 and 2006: a national follow-up survey. Crit Care 2007, 11:R124. Available at:, Accessed June 15, 2009. http://ccforum.com/content/11/6/R124.
78. Egan T.D., Lemmens H.J., Fiset P., et al. The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology 1993, 79:881-892.
79. Rosow C. Remifentanil: a unique opioid analgesic. Anesthesiology 1993, 79:875-876.
80. Kapila A., Glass P.S., Jacobs J.R., et al. Measured context-sensitive half-times of remifentanil and alfentanil. Anesthesiology 1995, 83:968-975.
81. Westmoreland C.L., Hoke J.F., Sebel P.S., et al. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology 1993, 79:893-903.
82. Pitsiu M., Wilmer A., Bodenham A., et al. Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. Br J Anaesth 2004, 92:493-503.
83. Dershwitz M., Rosow C.E. The pharmacokinetics and pharmacodynamics of remifentanil in volunteers with severe hepatic or renal dysfunction. J Clin Anesth 1996, 8:88S-90S.
84. Dumont L., Picard V., Marti R.A., et al. Use of remifentanil in a patient with chronic hepatic failure. Br J Anaesth 1998, 81:265-267.
85. Breen D., Karabinis A., Malbrain M., et al. Decreased duration of mechanical ventilation when comparing analgesia-based sedation using remifentanil with standard hypnotic-based sedation for up to 10 days in intensive care unit patients: a randomised trial [ISRCTN47583497]. Crit Care 2005, 9:R200-R210.
86. Evane T.N., Park G.R. Remifentanil in the critically ill. Anaesthesia 1997, 52:800-801.
87. Delvaux B., Ryckwaert Y., Van Boven M., et al. Remifentanil in the intensive care unit: tolerance and acute withdrawal syndrome after prolonged sedation. Anesthesiology 2005, 102:1281-1282.
88. Jacobi J., Fraser G.L., Coursin D.B., et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002, 30:119-141.
89. Dahaba A.A., Grabner T., Rehak P.H., et al. Remifentanil versus morphine analgesia and sedation for mechanically ventilated critically ill patients: a randomized double blind study. Anesthesiology 2004, 101:640-646.
90. Baillard C., Cohen Y., Le Toumelin P., et al. Ann Fr Anesth Reanim 2005, 24:480-486. [in French].
91. Muellejans B., Lopez A., Cross M.H., et al. Remifentanil versus fentanyl for analgesia-based sedation to provide patient comfort in the intensive care unit: a randomized, double-blind controlled trial [ISRCTN43755713]. Crit Care 2004, 8:R1-R11.
92. Muellejans B., Matthey T., Scholpp J., et al. Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial. Crit Care 2006, 10:R91. Available at:, Accessed June 15, 2009. http://ccforum.com/content/10/3/R91.
93. Karabinis A., Mandragos K., Stergiopoulos S., et al. Safety and efficacy of analgesia-based sedation with remifentanil versus standard hypnotic-based regimens in intensive care unit patients with brain injuries: a randomised, controlled trial [ISRCTN50308308]. Crit Care 2004, 8:R268-R280.
94. Engelhard K., Reeker W., Kochs E., et al. Effect of remifentanil on intracranial pressure and cerebral blood flow velocity in patients with head trauma. Acta Anaesthesiol Scand 2004, 48:396-399.
95. Leone M., Albanese J., Viviand X., et al. The effects of remifentanil on endotracheal suctioning-induced increases in intracranial pressure in head-injured patients. Anesth Analg 2004, 99:1193-1198. table of contents.
96. Domino E.F., Chodoff P., Corssen G. Pharmacologic effects of Ci-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther 1965, 6:279-291.
97. Malchow R.J., Black I.H. The evolution of pain management in the critically ill trauma patient: emerging concepts from the global war on terrorism. Crit Care Med 2008, 36:S346-S357.
98. Gelissen H.P., Epema A.H., Henning R.H., et al. Inotropic effects of propofol, thiopental, midazolam, etomidate, and ketamine on isolated human atrial muscle. Anesthesiology 1996, 84:397-403.
99. Saegusa K., Furukawa Y., Ogiwara Y., et al. Pharmacologic analysis of ketamine-induced cardiac actions in isolated, blood-perfused canine atria. J Cardiovasc Pharmacol 1986, 8:414-419.
100. Reich D.L., Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 1989, 36:186-197.
101. Chen R.M., Chen T.L., Lin Y.L., et al. Ketamine reduces nitric oxide biosynthesis in human umbilical vein endothelial cells by down-regulating endothelial nitric oxide synthase expression and intracellular calcium levels. Crit Care Med 2005, 33:1044-1049.
102. Yli-Hankala A., Kirvela M., Randell T., et al. Ketamine anaesthesia in a patient with septic shock. Acta Anaesthesiol Scand 1992, 36:483-485.
103. Doenicke A., Angster R., Mayer M., et al. Anaesthesist 1992, 41:597-603. [in German].
104. Park G.R., Manara A.R., Mendel L., et al. Ketamine infusion. Its use as a sedative, inotrope and bronchodilator in a critically ill patient. Anaesthesia 1987, 42:980-983.
105. Sarma V.J. Use of ketamine in acute severe asthma. Acta Anaesthesiol Scand 1992, 36:106-107.
106. Mazar J., Rogachev B., Shaked G., et al. Involvement of adenosine in the antiinflammatory action of ketamine. Anesthesiology 2005, 102:1174-1181.
107. Gurfinkel R., Czeiger D., Douvdevani A., et al. Ketamine improves survival in burn injury followed by sepsis in rats. Anesth Analg 2006, 103:396-402. table of contents.
108. Kawasaki T., Ogata M., Kawasaki C., et al. Ketamine suppresses proinflammatory cytokine production in human whole blood in vitro. Anesth Analg 1999, 89:665-669.
109. Takenaka I., Ogata M., Koga K., et al. Ketamine suppresses endotoxin-induced tumor necrosis factor-alpha production in mice. Anesthesiology 1994, 80:402-408.
110. Pfenninger E., Grunert A., Bowdler I., et al. The effect of ketamine on intracranial pressure during haemorrhagic shock under the conditions of both spontaneous breathing and controlled ventilation. Acta Neurochir (Wien) 1985, 78:113-118.
111. Schwedler M., Miletich D.J., Albrecht R.F. Cerebral blood flow and metabolism following ketamine administration. Can Anaesth Soc J 1982, 29:222-226.
112. Himmelseher S., Durieux M.E. Revising a dogma: ketamine for patients with neurological injury?. Anesth Analg 2005, 101:524-534. table of contents.
113. Strebel S., Kaufmann M., Maitre L., et al. Effects of ketamine on cerebral blood flow velocity in humans. Influence of pretreatment with midazolam or esmolol. Anaesthesia 1995, 50:223-228.
114. Albanese J., Arnaud S., Rey M., et al. Ketamine decreases intracranial pressure and electroencephalographic activity in traumatic brain injury patients during propofol sedation. Anesthesiology 1997, 87:1328-1334.
115. Hijazi Y., Bodonian C., Bolon M., et al. Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury. Br J Anaesth 2003, 90:155-160.
116. Himmelseher S., Durieux M.E. Ketamine for perioperative pain management. Anesthesiology 2005, 102:211-220.
117. Bowdle T.A., Radant A.D., Cowley D.S., et al. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 1998, 88:82-88.
118. Hartvig P., Valtysson J., Lindner K.J., et al. Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin Pharmacol Ther 1995, 58:165-173.
119. Tucker A.P., Kim Y.I., Nadeson R., et al. Investigation of the potentiation of the analgesic effects of fentanyl by ketamine in humans: a double-blinded, randomised, placebo controlled, crossover study of experimental pain[ISRCTN83088383]. BMC Anesthesiol 2005, 5:2. Available at:, Accessed June 15, 2009. http://www.biomedcentral.com/1471-2253/5/2.
120. Badrinath S., Avramov M.N., Shadrick M., et al. The use of a ketamine-propofol combination during monitored anesthesia care. Anesth Analg 2000, 90:858-862.
121. Friedberg B.L. Propofol-ketamine technique: dissociative anesthesia for office surgery (a 5-year review of 1264 cases). Aesthetic Plast Surg 1999, 23:70-75.
122. Morse Z., Sano K., Kanri T. Effects of a midazolam-ketamine admixture in human volunteers. Anesth Prog 2004, 51:76-79.
123. Guillou N., Tanguy M., Seguin P., et al. The effects of small-dose ketamine on morphine consumption in surgical intensive care unit patients after major abdominal surgery. Anesth Analg 2003, 97:843-847.
124. Lahtinen P., Kokki H., Hakala T., et al. S(+)-ketamine as an analgesic adjunct reduces opioid consumption after cardiac surgery. Anesth Analg 2004, 99:1295-1301. table of contents.
125. Zielmann S., Grote R. Anaesthesist 1995, 44(Suppl 3):S549-S558. [in German].
126. Li J., Simone D.A., Larson A.A. Windup leads to characteristics of central sensitization. Pain 1999, 79:75-82.
127. Oye I. Ketamine analgesia, NMDA receptors and the gates of perception. Acta Anaesthesiol Scand 1998, 42:747-749.
128. Mao J., Price D.D., Mayer D.J. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995, 62:259-274.
129. Stubhaug A., Breivik H., Eide P.K., et al. Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery. Acta Anaesthesiol Scand 1997, 41:1124-1132.
130. Joly V., Richebe P., Guignard B., et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology 2005, 103:147-155.
131. Angst M.S., Clark J.D. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006, 104:570-587.
132. De Kock M., Lavand'homme P., Waterloos H. 'Balanced analgesia' in the perioperative period: is there a place for ketamine?. Pain 2001, 92:373-380.
133. Lois F., De Kock M. Something new about ketamine for pediatric anesthesia?. Curr Opin Anaesthesiol 2008, 21:340-344.
134. McGhee L.L., Maani C.V., Garza T.H., et al. The correlation between ketamine and posttraumatic stress disorder in burned service members. J Trauma 2008, 64:S195-S198. [discussion: S7-8].
135. Hersack R.A. Ketamine's psychological effects do not contraindicate its use based on a patient's occupation. Aviat Space Environ Med 1994, 65:1041-1046.
136. Zarate C.A., Singh J.B., Carlson P.J., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.
137. De Hert S.G. Volatile anesthetics and cardiac function. Semin Cardiothorac Vasc Anesth 2006, 10:33-42.
138. Meiser A., Sirtl C., Bellgardt M., et al. Desflurane compared with propofol for postoperative sedation in the intensive care unit. Br J Anaesth 2003, 90:273-280.
139. Campagna J.A., Miller K.W., Forman S.A. Mechanisms of actions of inhaled anesthetics. N Engl J Med 2003, 348:2110-2124.
140. De Hert S.G., Cromheecke S., ten Broecke P.W., et al. Effects of propofol, desflurane, and sevoflurane on recovery of myocardial function after coronary surgery in elderly high-risk patients. Anesthesiology 2003, 99:314-323.
141. De Hert S.G., ten Broecke P.W., Mertens E., et al. Sevoflurane but not propofol preserves myocardial function in coronary surgery patients. Anesthesiology 2002, 97:42-49.
142. Belhomme D., Peynet J., Louzy M., et al. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation 1999, 100:II340-II344.
143. Bierman M.I., Brown M., Muren O., et al. Prolonged isoflurane anesthesia in status asthmaticus. Crit Care Med 1986, 14:832-833.
144. Johnston R.G., Noseworthy T.W., Friesen E.G., et al. Isoflurane therapy for status asthmaticus in children and adults. Chest 1990, 97:698-701.
145. Maltais F., Sovilj M., Goldberg P., et al. Respiratory mechanics in status asthmaticus. Effects of inhalational anesthesia. Chest 1994, 106:1401-1406.
146. Revell S., Greenhalgh D., Absalom S.R., et al. Isoflurane in the treatment of asthma. Anaesthesia 1988, 43:477-479.
147. Kong K.L., Bion J.F. Sedating patients undergoing mechanical ventilation in the intensive care unit-winds of change?. Br J Anaesth 2003, 90:267-269.
148. Millane T.A., Bennett E.D., Grounds R.M. Isoflurane and propofol for long-term sedation in the intensive care unit. A crossover study. Anaesthesia 1992, 47:768-774.
149. Kong K.L., Willatts S.M., Prys-Roberts C. Isoflurane compared with midazolam for sedation in the intensive care unit. BMJ 1989, 298:1277-1280.
150. Spencer E.M., Willatts S.M. Isoflurane for prolonged sedation in the intensive care unit; efficacy and safety. Intensive Care Med 1992, 18:415-421.
151. Rohm K.D., Wolf M.W., Schollhorn T., et al. Short-term sevoflurane sedation using the Anaesthetic Conserving Device after cardiothoracic surgery. Intensive Care Med 2008, 34:1683-1689.
152. Bito H., Atsumi K., Katoh T., et al. Effects of sevoflurane anesthesia on plasma inorganic fluoride concentrations during and after cardiac surgery. J Anesth 1999, 13:156-160.
153. Sackey P.V., Radell P.J., Granath F., et al. Bispectral index as a predictor of sedation depth during isoflurane or midazolam sedation in ICU patients. Anaesth Intensive Care 2007, 35:348-356.
154. Sackey P.V., Martling C.R., Granath F., et al. Prolonged isoflurane sedation of intensive care unit patients with the anesthetic conserving device. Crit Care Med 2004, 32:2241-2246.
155. Sackey P.V., Martling C.R., Carlsward C., et al. Short- and long-term follow-up of intensive care unit patients after sedation with isoflurane and midazolam-a pilot study. Crit Care Med 2008, 36:801-806.
156. Maccioli G.A., Cohen N.H. General anesthesia in the intensive care unit? Is it ready for "prime time"? Crit Care Med 2005, 33:687-688.
157. Berton J., Sargentini C., Nguyen J.L., et al. AnaConDa reflection filter: bench and patient evaluation of safety and volatile anesthetic conservation. Anesth Analg 2007, 104:130-134.
158. Murphy D.B., Sutton J.A., Prescott L.F., et al. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology 1997, 87:765-770.
159. Yuan C.S., Foss J.F., O'Connor M., et al. Effects of low-dose morphine on gastric emptying in healthy volunteers. J Clin Pharmacol 1998, 38:1017-1020.
160. Moss J., Rosow C.E. Development of peripheral opioid antagonists' new insights into opioid effects. Mayo Clin Proc 2008, 83:1116-1130.
161. Ho W.Z., Guo C.J., Yuan C.S., et al. Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes. J Pharmacol Exp Ther 2003, 307:1158-1162.